Current clinical trials in amyotrophic lateral sclerosis

被引：28

作者：

Bhatt, Jaydeep M. ^{[1
]}

Gordon, Paul H. ^{[1
]}

机构：

[1] Columbia Univ, Dept Neurol, Neurol Inst, Eleanor & Lou Gehrig MDA ALS Res Ctr, New York, NY 10032 USA

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2007年 / 16卷 / 08期

基金：

美国国家卫生研究院;

关键词：

amyotrophic lateral sclerosis; clinical trials; excitotoxicity; minocycline; motor neuron degeneration; neuroprotective agents; neurotrophic factors; riluzole;

D O I：

10.1517/13543784.16.8.1197

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Amyotrophic lateral sclerosis is caused by selective degeneration of motor neurons in the brain and spinal cord. There are still no other effective therapies 10 years after the approval of riluzole for the treatment of amyotrophic lateral sclerosis, but advances in drug development and screening are substantially increasing the number of potential therapeutic agents. This review provides an overview of clinical trial methodology in annyotrophic lateral sclerosis followed by a systematic evaluation of drugs that are presently in Phase I, II and III clinical trials. There is an emphasis on the scientific evidence supporting the selection of each drug being tested, as well as on trial design.

引用

页码：1197 / 1207

页数：11

共 92 条

[51] Minocycline slows disease progression in a mouse model of arnyotrophic lateral sclerosis [J].

Kriz, J ;

Nguyen, MD ;

Julien, JP .

NEUROBIOLOGY OF DISEASE, 2002, 10 (03) :268-278

[52] Dose-ranging study of riluzole in amyotrophic lateral sclerosis [J].

Lacomblez, L ;

Bensimon, G ;

Leigh, PN ;

Guillet, P ;

Meininger, V .

LANCET, 1996, 347 (9013) :1425-1431

[53] Effect of recombinant human insulin-like growth factor-I on progression of ALS - A placebo-controlled study [J].

Lai, EC ;

Felice, KJ ;

Festoff, BW ;

Gawel, MJ ;

Gelinas, DF ;

Kratz, R ;

Murphy, MF ;

Natter, HM ;

Norris, FH ;

Rudnicki, SA .

NEUROLOGY, 1997, 49 (06) :1621-1630

[54] Talampanel, a new antiepileptic drug: Single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy [J].

Langan, YM ;

Lucas, R ;

Jewell, H ;

Toublanc, N ;

Schaefer, H ;

Sander, JWAS ;

Patsalos, PN .

EPILEPSIA, 2003, 44 (01) :46-53

[55]

LANIUS RA, 1995, J NEUROCHEM, V65, P927

[56] A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS [J].

Levy, G ;

Kaufmann, P ;

Buchsbaum, R ;

Montes, J ;

Barsdorf, A ;

Arbing, R ;

Battista, V ;

Zhou, X ;

Mitsumoto, H ;

Levin, B ;

Thompson, JLP .

NEUROLOGY, 2006, 66 (05) :660-663

[57]

LOWE J, 1997, GREENFIELDS NEUROPAT, P281

[58]

LOWE WL, 1996, SCI AM SCI MED, P62

[59] The interaction between neuroactive steroids and the σ1 receptor function:: behavioral consequences and therapeutic opportunities [J].

Maurice, T ;

Urani, A ;

Phan, VL ;

Romieu, P .

BRAIN RESEARCH REVIEWS, 2001, 37 (1-3) :116-132

[60]

McGuire V, 2006, AMYOTROPHIC LATERAL, P17

← 1 2 3 4 5 6 7 8 9 10 →